These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7590480)

  • 1. Cisplatin, adriamycin, etoposide, megestrol acetate versus melphalan, 5-fluorouracil, medroxyprogesterone acetate in the treatment of endometrial carcinoma.
    Cornelison TL; Baker TR; Piver MS; Driscoll DL
    Gynecol Oncol; 1995 Nov; 59(2):243-8. PubMed ID: 7590480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of doxorubicin, 5-fluorouracil, etoposide, and cisplatin in advanced or recurrent endometrial carcinoma.
    Pierga JY; Diéras V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Scholl SM; Garcia-Giralt E; Pouillart P
    Gynecol Oncol; 1997 Aug; 66(2):246-9. PubMed ID: 9264570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapy of advanced endometrial cancer].
    Okada H; Yamamoto T
    Gan To Kagaku Ryoho; 1990 Sep; 17(9):1848-55. PubMed ID: 2144105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of recurrent and metastatic endometrial cancer with cisplatin, doxorubicin, cyclophosphamide, and megestrol acetate.
    Hoffman MS; Roberts WS; Cavanagh D; Praphat H; Solomon P; Lyman GH
    Gynecol Oncol; 1989 Oct; 35(1):75-7. PubMed ID: 2477317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melphalan, 5-fluorouracil, and medroxyprogesterone acetate in metastatic endometrial carcinoma.
    Piver MS; Lele SB; Patsner B; Emrich LJ
    Obstet Gynecol; 1986 Feb; 67(2):261-4. PubMed ID: 3945437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of cisplatin, adriamycin and etoposide chemotherapy in patients with recurrent and metastatic endometrial cancer.
    Bilgin T; Ozan H; Kara HF
    Eur J Gynaecol Oncol; 2004; 25(3):379-80. PubMed ID: 15171324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of cisplatin, adriamycin, and etoposide for metastatic endometrial adenocarcinoma.
    Piver MS; Fanning J; Baker TR
    Am J Clin Oncol; 1991 Jun; 14(3):200-2. PubMed ID: 2031506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of advanced or recurrent endometrial adenocarcinoma with cyclophosphamide, doxorubicin, cis-Platinum, and megestrol acetate.
    Lovecchio JL; Averette HE; Lichtinger M; Townsend PA; Girtanner RW; Fenton AN
    Obstet Gynecol; 1984 Apr; 63(4):557-60. PubMed ID: 6538327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of advanced or recurrent endometrial carcinoma with combination of etoposide, cisplatin, and 5-fluorouracil: a phase II study.
    Pierga JY; Dieras V; Paraiso D; Dorval T; Palangie T; Beuzeboc P; Jouve M; Scholl SM; Garcia-Giralt E; Pouillart P
    Gynecol Oncol; 1996 Jan; 60(1):59-63. PubMed ID: 8557229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of outcomes in patients treated with multi-agent regiments of cisplatin, adriamycin, and VP-16 versus carboplatin and paclitaxel for advanced and recurrent endometrial cancer.
    Olawaiye AB; Godoy HE; Shahzad MM; Rauh-Hain JA; Lele SB; Odunsi K
    Eur J Gynaecol Oncol; 2012; 33(5):477-9. PubMed ID: 23185791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study.
    Rowland KM; Loprinzi CL; Shaw EG; Maksymiuk AW; Kuross SA; Jung SH; Kugler JW; Tschetter LK; Ghosh C; Schaefer PL; Owen D; Washburn JH; Webb TA; Mailliard JA; Jett JR
    J Clin Oncol; 1996 Jan; 14(1):135-41. PubMed ID: 8558188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
    Lentz SS; Brady MF; Major FJ; Reid GC; Soper JT
    J Clin Oncol; 1996 Feb; 14(2):357-61. PubMed ID: 8636744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review of systemic therapy for advanced or recurrent endometrial cancer.
    Carey MS; Gawlik C; Fung-Kee-Fung M; Chambers A; Oliver T;
    Gynecol Oncol; 2006 Apr; 101(1):158-67. PubMed ID: 16434086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin, doxorubicin hydrochloride, and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma.
    Smith MR; Peters WA; Drescher CW
    Am J Obstet Gynecol; 1994 Jun; 170(6):1677-81; discussion 1681-2. PubMed ID: 8203425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant chemotherapy including cisplatin in endometrial carcinoma.
    Fujimura H; Kikkawa F; Oguchi H; Nakashima N; Mizutani S
    Gynecol Obstet Invest; 2000; 50(2):127-32. PubMed ID: 10965198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboplatin, methotrexate and 5-fluorouracil in combination with medroxyprogesterone acetate (JMF-M) in the treatment of advanced or recurrent endometrial carcinoma: A Hellenic cooperative oncology group study.
    Bafaloukos D; Aravantinos G; Samonis G; Katsifis G; Bakoyiannis C; Skarlos D; Kosmidis P
    Oncology; 1999 Apr; 56(3):198-201. PubMed ID: 10202274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer.
    Pautier P; Vergote I; Joly F; Melichar B; Kutarska E; Hall G; Lisyanskaya A; Reed N; Oaknin A; Ostapenko V; Zvirbule Z; Chetaille E; Geniaux A; Shoaib M; Green JA
    Int J Gynecol Cancer; 2017 Feb; 27(2):258-266. PubMed ID: 27870712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma.
    Karagol H; Saip P; Uygun K; Kucucuk S; Aydiner A; Topuz E
    Med Oncol; 2006; 23(4):543-8. PubMed ID: 17303913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of recurrent and metastatic adenocarcinoma of the endometrium with cisplatin, doxorubicin, cyclophosphamide, and medroxyprogesterone acetate.
    Fung MF; Krepart GV; Lotocki RJ; Heywood M
    Obstet Gynecol; 1991 Dec; 78(6):1033-8. PubMed ID: 1945203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel/carboplatin versus cyclophosphamide/adriamycin/cisplatin as postoperative adjuvant chemotherapy for advanced endometrial adenocarcinoma.
    Hidaka T; Nakamura T; Shima T; Yuki H; Saito S
    J Obstet Gynaecol Res; 2006 Jun; 32(3):330-7. PubMed ID: 16764625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.